

13 June 2023

Company Announcements Office
Australian Securities Exchange

Breathe Life Sciences (BLS) Launches BLS Clinics – Online Healthcare

Highlights

- **BLS launches online healthcare with technology partner InstantScripts**
- **InstantScripts technology is registered via Australia Digital Health Agency (ADHA)**
- **InstantScripts has a network of over 120 doctors that have served over 1 million Australians**
- **BLS Clinics now fulfilling scripts for plant based therapies through partner pharmacies**

Bioxyne Limited (ASX: BXN) (Bioxyne or Company) is pleased to advise the launch of its online healthcare business, BLS Clinics, with technology partner InstantScripts.

BLS Clinics, developed in co-operation between Breathe Life Sciences and Powered by InstantScripts, was created as an online telehealth medical platform dedicated to providing plant-based health care consultations for patients suffering from chronic health conditions.

InstantScripts' market leading technology supports over one thousand telephone and video based medical consultations with Australians every day.

Plant-based therapy encompasses a wide range of compounds derived from plants, and often the plants (or flowers) themselves. These products can be prescribed by authorised prescribers in Australia to treat patient conditions. BLS Clinic's authorised prescribers can prescribe plant-based therapies to eligible patients in a variety of forms including oils, capsules & dried flower, and containing ingredients including cannabinoids, flavanoids, and terpenes.

In Australia, BLS holds licenses to import, export, wholesale, and manufacture Schedule 3, 4, and 8 controlled substances including medicinal cannabis and ketamine, and is awaiting its TGA Pharmaceutical GMP inspection scheduled for September 2023.

Sam Watson commented *"BLS Clinics allows patients to access alternative medicines to treat chronic health conditions through a delivery system that is safe and regulated. Our mission is to democratise healthcare and pharma to be a global leader in the manufacture and supply of novel medicines, healthcare and health-tech solutions, pioneering new age treatments and cures for both mental and physical diseases, and to empower patients with advanced technology for screening, access, suitability, and treatment."*

The Company is not able to determine the financial impact of the launch of BLS Clinics for the purposes of materiality as at the date of this announcement.

This announcement has been approved for release to the ASX by the Board.

For further information contact:

Sam Watson
Managing Director
Bioxyne Limited
sam@breathelifesciences.com

Guy Robertson
Chief Financial Officer
Bioxyne Limited
guy@bioxyne.com

About Bioxyne

Bioxyne Limited (ASX:BXN) is an Australian health and wellness products company (incorporated in 2000) with a focus on clinically effective health and wellness products particularly in the gut and immune health areas.

Bioxyne is in the consumer dietary supplements and functional foods markets through its proprietary probiotic, *Lactobacillus fermentum* VRI-003 (PCC®), and through its direct sales business trading as Bioxyne International, the Company has developed a range of functional food products containing ingredients sourced primarily from New Zealand.

Bioxyne's probiotic business is supported by a manufacturing and distribution agreement with Chr. Hansen (Denmark) a global leader in the manufacturing of natural food additives and supplements products for the food, health, pharmaceutical and agriculture industries.

Bioxyne has a distribution agreement for PCC® with Nu-Skin Enterprises (USA) a successful worldwide direct selling company. For more information on Bioxyne, please visit <https://bioxyne.com>

About Breathe Life Sciences (BLS)

BLS is an Australian incorporated company that has wholly-owned subsidiaries in Japan, France, Czechia, Switzerland, United Kingdom and Australia (together, the **BLS Group**).

In Australia, the BLS Group (via the subsidiary BLS Wholesalers Pty Ltd) holds controlled substance licenses to import, export, wholesale and manufacture Schedule 3,4 and 8 poisons (Medicinal cannabis), and operates a wholesale distribution model as well as direct to patient supply of prescribed medications via blsclinics.com.au. BLS Wholesalers also holds a manufacturing licence issued by the Queensland government for schedule 3,4, and 8 poisons, ISO-7 audited clean rooms, and a pending pharmaceutical GMP (Good Manufacturing Practices) audit.

Outside of Australia the BLS Group operates a health and wellness products and brands business focussed on naturally derived active nutraceuticals, wellness and lifestyle supplements and cannabidiol (CBD) based therapeutic goods.

The BLS Group commercialises products containing active ingredients, such as cannabinoids, novel food supplements, mushroom extracts, vitamins, Manuka Honey and probiotic supplements. It primarily operates in the UK, Europe and Japan, and engages in the following activities:

- (a) owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand – Dr Watson is an internationally recognized leading CBD, health and lifestyle brand. Dr Watson products consist of cannabis-based food supplements and lifestyle products, cosmetics, functional mushrooms and nootropics;
- (b) contract manufacture and wholesale of raw materials and cannabinoid extracts in Japan, UK and Europe;
- (c) white label manufacture of third-party wellness and supplements brands in Japan, UK and Europe in company-owned facilities;
- (d) research and development for third party customers;
- (e) direct sales via online and wholesale sales of BLS-owned consumer brands, such as Dr Watson® (drwatsoncbd.com), via The Organic Pharmacy (theorganicpharmacy.com), VPZ (vpz.co.uk), NHS (National Hemp Service), Amazon.co.uk, Amazon.co.jp, Rakuten.co.jp), NOL (nolcbln.com), Apothecary CBD (via Amazon UK), Essentials CBD (via Amazon UK); and
- (f) online healthcare business BLS Clinics together with technology partner InstantScripts – see blsclinics.com.au